Highlights of the important and interesting in the world of healthcare:
It’s election day. Research!America offers to help you better understand your candidates’ positions on issues in health and research.
No magic bullet for diabetes. Amgen Inc. (NASDAQ:AMGN) Chief Executive Kevin Sharer said Monday at the Cleveland Clinic’s medical innovation summit on obesity and diabetes that he doesn’t envision the drug industry developing new medicines over the next decade that stem the rising tide of diabetes, according to Dow Jones.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Should genes be patentable? The U.S. Department of Justice’s reversal of longstanding policy with its recent statement that human and other genes should be ineligible for patents because they are part of nature could have huge impacts on medicine and the biotechnology industry, according to the New York Times.
Got germs? GoJo Industries Inc. in Akron, Ohio, has reacquired the Purell hand sanitizer brand from Johnson & Johnson’s consumer products division, Crain’s Cleveland Business reports. Just in time for cold and flu season.
Pounding on Medicare’s door. Sen. Charles Grassley (R-Iowa) shot off another letter to CMS Administrator Dr. Donald Berwick, focusing on possible conflicts of interest among Medicare contractors that conduct fraud investigations, according to FierceHealthcare.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Credit thumbs up for HCA. Credit rating agency Fitch raised its sights on the debt of HCA Inc. because the for-profit hospital chain could significantly pay down debt with $2.5 billion in proceeds it expects from its third initial public offering, according to Bloomberg Businessweek.
